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Abstract
Background and Aim: Severe ulcerative colitis (UC) is potentially life threatening
and is associated with significant morbidity. TNF-/ inhibitors (Infliximab) were intro-
duced in Australia for the management of medically resistant, acute, severe flares of
UC in 2008. The aim of this study is to assess the efficacy of Infliximab in preventing
emergent and emergency colectomies for patients with moderate to severe UC by
comparing colectomy rates before and after its introduction at our institution.
Methods: This was a retrospective cohort study of all patients who were admitted to
the Royal Perth Hospital with a flare of UC between 2002 and 2017. Patients were
divided into two cohorts: those admitted prior to the introduction of Infliximab (pre-
2008) and those admitted after. We compared data between these two groups, includ-
ing age, gender, length of admission, use of Infliximab, colectomy, and complications
of surgery. We defined emergency surgery as requiring surgery during the index
admission and emergent surgery as an operation within 54 weeks.
Results: A total of 313 UC cases from 2002 to 2017 were analyzed. There was a
decrease in emergency and emergent colectomies from 19.4 to 8% in the post-2008
cohort (P = 0.008). Furthermore, there was a decrease in the proportion of operations
performed as emergencies, from 36 to 20%. This resulted in a significantly reduced
length of stay (13.4–9.7 days, P < 0.05) and complication rate (36 to 20%, P < 0.05).
Conclusion: Overall, the need for emergency and emergent operations has drastically
reduced at our institution with the introduction of Infliximab. This study has con-
firmed the efficacy of Infliximab in reducing colectomy rates at our institution.
Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease in the
inflammatory bowel disease (IBD) spectrum of the colon and rec-
tum. In Australia, the annual incidence of UC is 17.4 per
100 000, and there are currently 33 000 Australians living with
the disease.1
The pathogenesis of IBD is thought to be a result of the
dysregulation of the mucosal immune system.2 Although the
exact mechanism by which the inflammatory cascade is stimu-
lated in IBD is unknown, studies have shown that TNF-/ medi-
ates inflammation. TNF-α blockade has a restorative function in
the suppressive action of regulatory T-cells, which is the basis of
its use in IBD.3
The use of TNF-α inhibitors (Infliximab) in the setting of
moderate to severe flares of UC was approved by the Therapeutic
Guidelines Australia (TGA) in February 2007. Its use is highly
regulated given that the cost of a single 100-mg injection is
$507.42. To be eligible, adult patients must first be clinically
scored by the Truelove and Witts criteria as having severe dis-
ease, have a Mayo Score of >6, or have had a positive docu-
mented response previously to TNF-/ inhibitors.
Only a few studies have directly compared the incidence
of colectomies before and after the introduction of this
drug.4There are no similar studies in an Australian context.
Pooled data from ACT-1 and -2 showed a 7% absolute risk
reduction and a hazard ratio of 0.59 for colectomies when com-
paring TNF-alpha inhibitor use and placebo.5,6
The aim of this study is to assess the efficacy of Infliximab
in preventing colectomies in the emergency setting for patients
with moderate to severe UC by comparing colectomy rates
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before and after the introduction of Infliximab at an Australian
institution.
Methods
Data collection. A retrospective cohort study was under-
taken of patients who were admitted to the Royal Perth Hospital
with an acute flare of ulcerative colitis. The study period was
from 1 July 2002 to 1 July 2017. All admissions to the hospital
for an acute flare of UC, which were biopsy proven, in patients
aged >16 years were included. Patients with Crohn’s disease,
nonspecific colitis, and all admissions where the primary diagno-
sis was not consistent with an acute flare of UC were excluded.
Admissions were identified using The Open Web Admin-
istration System (TOPAS) and WebPAS (replaced ToPAS from
2012). The International Statistical Classification of Diseases and
Related Health Problems 10th Revision, Australian Modification
(ICD-10-AM) codes: K51.0 Ulcerative (acute) pancolitis; K51.2
Ulcerative (acute) proctitis; K51.3 Ulcerative (chronic) rec-
tosigmoiditis; K51.4 Inflammatory polyps; K51.5 left sided coli-
tis; K51.8 Other UC; and K51.9 UC, unspecified were used to
search this database. A total of 3117 admissions were identified.
After applying the exclusion criteria, 313 admissions were eligi-
ble for analysis.
The variables extracted during chart review included age
at admission, gender, length of admission, medication used (cor-
ticosteroids, azathioprine/ 6-MP, Ciclosporin, 5-ASA), use of
TNF-/ inhibitors, complications of TNF-/ inhibitors, cole-
ctomy, complications of surgery, and death. Each admission was
also scored according to the Truelove and Witts classification7 as
this is the accepted criteria for approval of TNF-/ inhibitor use
in IBD and is easily extractable from medical records. If patients
underwent a colectomy, the timing was categorized as Emer-
gency Colectomy or Emergent Colectomy (within 54 weeks of
admission). There are currently no internationally accepted defi-
nitions to distinguish semiurgent colectomies from true elective
colectomies. The 54-week mark was chosen because the ACT-1
and ACT-2 trials demonstrated the maximal efficacy of
Infliximab at weeks 30 and 54.8 An emergent colectomy was
therefore defined as any semielective colectomy performed
within 54 weeks of an admission for acute colitis. Admissions
that eventually required an elective colectomy at the end of the
study period were also recorded for subgroup analysis. Admis-
sions were then divided into two cohorts: pre-Infliximab use
(2007 and before) and postapproval for Infliximab use (2008
onward).
Statistical analysis. Frequency and proportion of
colectomies, use of Infliximab, and severity of UC on admission
were assessed. Chi-square tests were used to determine if there
was any difference in the proportions of these measures prior to
and following the introduction of Infliximab in 2008. Logistic
regression was then used to formally examine the relationship
between Infliximab and the rate of UC before and after 2008.
Odds ratios (ORs) and confidence intervals were presented as
model estimates. Data pertaining to hospital length of stay were
not normally distributed (Shapiro Wilk P < 0.001) and were log-
transformed. A general linear model (GLM) was then used to
investigate whether the introduction of Infliximab in 2008 had
any impact on patient’s hospital length of stay. The age at which
UC was presented in patients and the severity of the condition
were also adjusted for and included in both the logistic regres-
sion model and the GLM. Significance of variables was achieved
if P < 0.05.
Results
A total of 313 UC cases from 2002 to 2017 were collated and
analyzed. (Table 1). The number of UC admissions pre- and
post-Infliximab was 62 and 251, respectively. The median inter-
quartile range (IQR) age at presentation was 35.1 (27.1–47.6)
years. One in three admissions was moderate (n = 100, 32%),
while the remaining were severe (n = 213, 68%). There were no
admissions for mild flares of UC.
There was a gradual increase in the number of admissions
involving the use of Infliximab from 2008. In the first 4 years
since the introduction of Infliximab, one in four cases (16 of
53, 23%) involved the use of Infliximab, which later increased to
one in three (19 of 55, 34.5%) cases in 2012–2013 and then to
almost one in two cases (61 of 127, 48%) from 2014 to 2017.
Furthermore, 47% (99 of 213) of all severe cases of UC involved
infliximab. There was only a single instance where Infliximab
was used for moderate UC. This patient had previously presented
with a severe flare and had already received Infliximab prior to
this admission.
Approximately 13% (n = 28) of all severe cases required
emergency or emergent colectomies, of which 71% (20 of 28)
underwent emergency surgery. Only 4% (n = 4) of patients with
moderate UC underwent surgery.
Table 1 Patient demographics
Demographics Pre-2008 (62) 2008 onwards (251) P value
Age (mean) 39.8 38.5 0.55
Age (SD) 16.5 15.4 0.406
LOS (mean) 10.8 6.2 0.004
LOS (SD) 11.9 5.5 <0.001
Prednisolone 62 (100%) 236 (94%) 0.055
Azathioprine 24 (38.7%) 101 (40.2%) 0.756
5-ASA 57 (91.9%) 210 (83.7%) 0.175
TNF-α 4 (6.5%) 155 (61.8%) <0.001
Ciclosporin 9 (14.5%) 1 (0.4%) <0.001
Table 2 Primary outcomes
Emergency/emergent
colectomy
No Yes P-value
Infliximab Preintroduction 50 (80.6%) 12 (19.4%) 0.008†
Postintroduction 231 (92.0%) 20 (8.0%)
Severity of
UC
Moderate 96 (96.0%) 4 (4.0%) 0.013†
Severe 185 (86.9%) 28 (13.1%)
†Chi-square test.
UC, ulcerative colitis.
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From 2002 to 2007, 19.4% of UC admissions eventuated
in emergency/emergent surgery, and this decreased to only 8%
from 2008 onward (Table 2). Figure 1 illustrates the reduction in
the percentage of cases post-2008 requiring surgery in compari-
son to pre-2008, particularly with emergency and elective surger-
ies. The rate of surgery throughout the years in the post-2008
period remained low, except for during 2014–2015 (15%),
despite comparable proportions of severe cases (n = 45, 62%).
After adjusting for severity and age of patients presenting
with UC, the logistic model indicated that there was a 72%
reduction in the emergency colectomy rate (OR = 0.28,
P = 0.005) and a 62% reduction in the rate of
emergency/emergent colectomies (OR = 0.38, P = 0.017) since
the introduction of Infliximab in 2008. Patients with severe UC
were 3.5–5 times more likely to undergo emergent or emergency
surgery (P < 0.05) compared to those with moderate disease. The
age at presentation had no significant influence on the likelihood
of emergency and/or emergent surgery (P > 0.05) (Table 3).
Only 4 of 159 admissions (0.03%) receiving Infliximab
had recorded related complications. Two had a severe drug reac-
tion necessitating immediate cessation, and two had significant
infections secondary to immunosuppression. One patient had a
peritonsillar abscess and the other oral candidiasis. Ten patients
experienced surgical complications, which ranged from superfi-
cial wound infections to intra-abdominal collections (Table 4).
Complications were scored using the Clavien-Dindo classifica-
tion.9 Only two patients who received Infliximab scored >3,
while all patients who had complications and did not receive
Infliximab scored >3. Overall, there was a 36.4% rate of compli-
cations for emergency colectomies compared to 20% for emer-
gent colectomies (Fig. 2). None of the elective operations within
these two cohorts had recorded complications. The observed
trend in the reduced complication rate was evident. (P < 0.095).
There was only one mortality, and this occurred in the pre-2008
cohort following emergency colectomy. The patient was 73 years
of age, had significant comorbidities, and presented with a severe
flare of UC.
In relation to average length of stay (aLOS), the GLM dem-
onstrated a significant year × severity interaction (P < 0.033),
n = 44, 71%
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Figure 1 Admission requiring/not requiring surgery pre- and post-
2008. , elective; , emergent, , emergency; , no surgery.
Table 3 Logistic regression modeling of emergency and emergency/emergent colectomy pre- and postintroduction of infliximab in 2008
Emergency colectomy only Emergency and emergent colectomy
Variable Category OR (95% CI) P-value OR (95% CI) P-value
Infliximab Preintroduction 1.00 (Ref) 1.00 (Ref)
Postintroduction 0.28 (0.11, 0.69) 0.005 0.38 (0.17, 0.84) 0.017
Severity of UC Moderate 1.00 (Ref) 1.00 (Ref)
Severe 4.82 (1.09, 21.26) 0.038 3.47 (1.17, 10.24) 0.024
Age at presentation Range 15–85 1.01 (0.98, 1.04) 0.502 1 (0.98, 1.03) 0.773
1.00 (Ref), reference level; CI, confidence interval; OR, odds ratio.
Table 4 List of surgical complications
Surgical
classification Surgical complications
TNF-/
inhibitor use
Clavien-Dindo
score
Emergent Small bowel perforation No 3b
Emergent Rectal stump leak Yes 3b
Emergency Rectal stump leak No 3b
Emergency Enterocutaneous fistula No 4b
Emergency Anastomotic leak No 3b
Emergency Intra-abdominal collection No 3b
Emergency Enterocutaneous fistula Yes 3b
Emergency Wound infection (superficial) Yes 1
Emergency Wound infection (superficial) Yes 1
Emergency Wound infection (superficial) Yes 1
n = 8, 
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n = 2, 
20%n = 14, 
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Figure 2 Postcolectomy complications. , no complication; ,
complication.
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where no significant difference in mean aLOS was observed
between admissions pre-2008 (8.1 days; 95% CI 5.6–11 days) and
post-2008 (8.3 days, 95% CI 6.7–10 days) for moderate UC cases;
however, a significant reduction in median length of stay (LOS)
was evident in severe UC cases post-2008 (9.7 days, 95% CI 8.3–
11.9 days) compared to pre-2008 (13.4 days, 95% CI 11.3–
15.8 days) (see Fig. 3).
Not unexpectedly, the aLOS (16.0 days, 95% CI 13.1–
19.3 days) for patients who underwent emergency surgery was
significantly higher than those who had emergent (8.9 days, 95%
CI 5.8–12.4 days) (P = 0.007) or medical management (5.7 days,
95% CI 5.0–6.4 days) (P < 0.001). The aLOS is also positively
correlated with the age at presentation of UC (P < 0.001).
Discussion
This study confirms the efficacy of Infliximab in reducing emergent
and emergency colectomy rates. Prior to the introduction of TNF-α
inhibitors, the emergency and emergent colectomy rate at our
institution was 19.4%. Our results have shown a significant
decline in the rate of emergency and emergent colectomies per-
formed at our institution to 8% post-2008, which is comparable to
other studies.4,6,10,11 There have been no prior studies on the effi-
cacy of TNF-/ inhibitors in preventing colectomies in Australia.
Although an overall reduction in both emergency and
emergent operations was observed, there was also a lower pro-
portion of patients requiring emergency surgery. In the pre-
Infliximab era, the proportion of emergency to emergent opera-
tions was 2 to 1. This has changed in the post-Infliximab era to
1.5 to 1. This meant an increased opportunity for laparoscopic
surgery while minimizing LOS, complications, and mortality,
which is more achievable in the semielective setting.12 There
was also a noticeable reduction in the rate of complications from
36% in emergency operations to 20% in emergent operations,
and no complications were identified in elective procedures. It is
for this reason that we believe the differentiation between emer-
gency and emergent colectomies was important.
It is well established that emergency colectomies in IBD
are associated with significantly higher morbidity and mortality
compared to the elective setting.12,13 Compounding this, the esti-
mated annual hospital cost for the treatment of IBD in Australia
is up to $100 million per annum.14 As such, this is an important
cohort of patients to study.
Although licensed for use in 2008, there was a gradual
increase in its use observed over the following years. This is likely
due to an increased awareness among prescribers and availability of
the drug. In 2013, a specialist referral unit for IBD was established
at this institution, which also saw a rise in the number of referrals
and admissions. This may partly explain the rise in acute admissions
observed in the 2013–2014 period, which can also be attributable to
an overall increase in the incidence of UC in Australia.1
The introduction of TNF-α inhibitors also resulted in a
shorter LOS for patients who were admitted with severe UC. For
patients admitted with moderate disease, there was no difference
in LOS, which may reflect the fact that only one patient in our
cohort with moderate disease was given Infliximab. Furthermore,
the average LOS was significantly longer in patients who under-
went emergency operations when compared to patients who
underwent emergent operations or had no surgery, which is con-
sistent with data published by Patel et al.12 This has therefore
had significant implications on local resources at this institution.
The cost of a 100 mg single dose of Infliximab in
Australia is $507.42.14 Due to the previously noted high cost of
each dose of Infliximab ($507.42), it is a highly regulated drug
and is reserved only for severe flares of UC that are resistant to
standard medical therapy. However, it is likely that the reduced
number of operations, LOS, and complications in our cohort of
patients in the post-Infliximab era will result in tangible savings
to the Australian health-care system, which may balance the cost
of TNF-/ therapy. Further research is required to confirm the
cost-effectiveness of the use of Infliximab in UC.
Limitations. This study was not without limitations. Being a
retrospective study, all data were obtained via medical notes and
patient information databases available. The data are therefore lim-
ited to the accuracy of the documentation on these platforms. This
may have had implications, particularly regarding the accuracy of
staging of the severity of acute flares. Our institution is one of
three public tertiary referral centers in Western Australia. Patients
often attend other institutions in the emergency setting, which may
have affected the accuracy of the number of admissions with UC
in our catchment area per year. Compounding this, some patients
may have eventually had their treatment at private hospitals whose
records are beyond the ethical approval of this study.
Conclusions
Overall, the need for emergency and emergent operations has drasti-
cally reduced at our institution with the introduction of TNF-alpha
inhibitors. For a patient who presents with severe colitis, the use of
this medication has increased the likelihood that he or she could be
managed medically or with an emergent/elective operation rather
than an emergency operation with all its associated risks and com-
plications. This study has confirmed the efficacy of TNF-alpha
inhibitors in reducing colectomy rates at our institution. This has
elicited a paradigm change in the management of patients presenting
with acute severe flares of UC, which were previously associated
with significant morbidity. Further cost analysis research would jus-
tify its use even more and assess the financial impact of TNF-alpha
inhibitors on the hospital system and patients.
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Figure 3 Average length of stay for moderate and severe ulcerative
colitis (UC) pre- and post-2008. The error bars represent the 95% CI.
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